Ignite Creation Date:
2024-05-06 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 2:25 PM
Study NCT ID:
NCT05245734
Status:
RECRUITING
Last Update Posted:
2024-04-18
First Post:
2022-01-06
Brief Title:
Human Anti-D rh Immunoglobulin Rhesoglobin Efficacy Safety and Some Pharmacokinetics Parameters in Pregnant Women
Sponsor:
Biopharma Plasma LLC
Organization:
Biopharma Plasma LLC
Study Overview
Official Title:
Open-label Multicenter International Study of the Efficacy and Safety of the Drug Rhesoglobin Human Anti-D rh Immunoglobulin Manufactured by Biopharma Plasma LLC Ukraine in Pregnant Women in the Antenatal and Postnatal Period in Routine Clinical Practice for the Prevention of Rh Sensitization With a Subgroup for Evaluation of Some Pharmacokinetic Parameters
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Rhesus conflict between mother and fetus is due to the different antigenic composition of erythrocytes During the first pregnancy sensitization of the mother to fetal erythrocytes rhesus D RhD antigens is formed During the next pregnancy fetal red blood cells are attacked by the mothers antibodies and fetalnewborn hemolytic disease develops The drug Rhesoglobin blocks the interaction of the fetal erythrocytes RhD antigen and the immune system of the mother and prevents the development of Rhesus sensitization
Detailed Description:
The screening stage The pregnant woman participant has to sign an informed consent After the signed informed consent procedure the patient is assessed for meeting the inclusion and non-inclusion exclusion criteria Patients who were included in the study are assessed according to additional criteria for inclusion in the Pharmacokinetics subgroup
The clinical stage
According to the study protocol patients receive two prophylactic doses of the study drug at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery Patients receive the second dose only in the case of the birth of an Rh-positive child Before and after each injection of the drug blood will be taken to control the level of anti-Rh0 D antibodies In the Pharmacokinetics subgroup additional blood samples will be taken to determine the following pharmacokinetic parameters
Serum clearance
Volume of distribution
AUC area under curve
Т12 α and β half-life time
Cmax maximumpeak serum concentration
Tmax time to reach the maximum serum concentration
Kel elimination rate constant
The final stage The patient should be monitored for 6 months 5 days after the last injection of the drug blood samples are taken after 3 and 6 months to assess sensitization to the Rh antigen
The clinical stage
According to the study protocol patients receive two prophylactic doses of the study drug at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery Patients receive the second dose only in the case of the birth of an Rh-positive child Before and after each injection of the drug blood will be taken to control the level of anti-Rh0 D antibodies In the Pharmacokinetics subgroup additional blood samples will be taken to determine the following pharmacokinetic parameters
Serum clearance
Volume of distribution
AUC area under curve
Т12 α and β half-life time
Cmax maximumpeak serum concentration
Tmax time to reach the maximum serum concentration
Kel elimination rate constant
The final stage The patient should be monitored for 6 months 5 days after the last injection of the drug blood samples are taken after 3 and 6 months to assess sensitization to the Rh antigen
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None